RP-2 |
RP-2 |
Phase Ⅰ |
Replimune, Bristol-Myers Squibb |
Solid tumours |
Details
|
KN-044 |
KN-044,KN044; KN 044 |
Phase Ⅰ |
Alphamab |
Solid tumours |
Details
|
ADU-1604 |
ADU-1604,ADU 1604,ADU1604 |
Phase Ⅰ |
Aduro BioTech |
Cancer |
Details
|
Ipilimumab/IDD-1 combination vaccine (Medarex/IDM) |
|
Phase Not Specified |
Medarex, IDM Pharma |
Prostate cancer |
Details
|
Abatacept (Orban Biotech) |
|
Phase Ⅱ |
The National Institute of Diabetes and Digestive and Kidney Diseases, Orban Biotech |
Type 1 diabetes |
Details
|
BMS-986249 |
BMS-986249 |
Phase Ⅱ |
CytomX Therapeutics, Bristol-Myers Squibb |
Solid tumours |
Details
|
MK-1308 |
MK-1308 |
Phase Ⅱ |
Merck Sharp & Dohme |
Advanced non small cell lung cancer |
Details
|
AK-104 |
AK-104,AK104 |
Phase Ⅱ |
Akeso Biopharma |
Solid tumours |
Details
|
Anti-CTLA-4 monoclonal antibody (Regeneron) |
REGN-4659 |
Phase Ⅰ |
Regeneron Pharmaceutical |
Non small cell lung cancer (NSCLC) |
Details
|
ONC-392 |
ONC-392 |
Phase Ⅱ |
OncoImmune |
Non small cell lung cancer (NSCLC), Solid tumours |
Details
|
KN-046 |
KN-046 |
Phase Ⅲ |
Alphamab |
Non small cell lung cancer (NSCLC) |
Details
|
Recombinant anti-CTLA-4 human monoclonal antibody (Henlius) |
|
Phase Ⅰ |
Shanghai Henlius Biotech |
Colorectal neoplasms, Advanced renal cell carcinoma (RCC), Melanoma |
Details
|
HBM-4003 |
HBM-4003 |
Phase Ⅰ |
Harbour BioMed |
Solid tumours |
Details
|
CS-1002 |
CS-1002,CS1002 |
Phase Ⅰ |
CStone Pharmaceuticals |
Solid tumours |
Details
|
RG 2077 |
|
Phase Ⅰ |
Repligen |
Diabetes, Graft versus host disease, Systemic lupus erythematosus, Multiple sclerosis (MS), Rheumatoid arthritis (RA), Idiopathic thrombocytopenic purpura (ITP) |
Details
|
BCD-217 |
BCD-217 |
Phase Ⅱ |
Biocad |
Melanoma |
Details
|
PRS-010 (Pieris) |
Pieries-110; PRS-010; PRS-030; PRS-055; PRS-056; PRS-070; PRS-090; PRS-110; PRS-130; PRS-190 |
Preclinical |
Pieris Pharmaceuticals, Syngenta |
Cancer |
Details
|
Recombinant human anti-CTLA-4 monoclonal antibody (Mab-Venture/ShuangLu Pharmaceutical) |
|
Phase Ⅰ |
Mab-Venture, Beijing ShuangLu Pharmaceutical |
Solid tumours |
Details
|
BT-001 |
BT-001 |
Preclinical |
Transgene, BioInvent International |
Solid tumours |
Details
|
XmAb-22841 |
XmAb-22841 |
Phase Ⅰ |
Xencor |
Cancer |
Details
|
ATOR-1144 |
ATOR-1144 |
Preclinical |
Alligator Bioscience |
hematological malignancies, Solid tumours |
Details
|
XmAb20717 |
XmAb-20717,XmAb 20717 |
Phase Ⅰ |
Xencor |
Solid tumours |
Details
|
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) |
|
Phase Ⅱ |
Changhai Hospital of Shanghai |
Pancreatic cancer |
Details
|
10B-10 |
10B-10 |
Preclinical |
Crown Bioscience, Jiangsu Qyuns Biotech, CBT |
Cancer |
Details
|
Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering) |
|
Phase Ⅱ |
Hualan Biological Engineering |
Metastatic melanoma |
Details
|
ATOR-1015 |
ATOR-1015; ADC-1015 |
Phase Ⅰ |
Alligator Bioscience |
Solid tumours |
Details
|
Anti-CTLA-4 antibody (Agenus) |
AGEN-1181 |
Phase Ⅰ |
Agenus |
Solid tumours |
Details
|
IDO-derived peptide vaccine/PD-L1-derived peptide vaccine |
IO-102/IO-103 |
Phase Ⅱ |
Herlev Hospital, IO Biotech |
Metastatic melanoma |
Details
|
MGD-019 (MacroGenics) |
MGD-019 |
Phase Ⅰ |
MacroGenics |
Solid tumours |
Details
|
BA-3071 |
BA-3071; CAB-CTLA-4 |
Preclinical |
BioAtla, BeiGene |
Cancer |
Details
|
IO-102 |
IO-102 |
Phase Ⅱ |
IO Biotech, Herlev Hospital, Merck Sharp & Dohme |
Non small cell lung cancer (NSCLC), Melanoma |
Details
|
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) |
|
Phase Ⅱ |
Shanghai Cell Therapy Research Institute |
Solid tumours |
Details
|
YH-001 |
YH-001 |
Phase Ⅰ |
Eucure Biopharma |
Advanced solid tumors |
Details
|
Ipilimumab biosimilar (Innovent Biologics) |
IBI-310 |
Phase Ⅲ |
Innovent Biologics |
Gastric cancer |
Details
|
B7-2/GM-CSF cancer gene therapy |
CIT |
Phase Ⅰ |
Radient |
Solid tumours |
Details
|
BCD-145 (Biocad) |
BCD-145 |
Phase Ⅰ |
Biocad |
Metastatic melanoma |
Details
|
Tremelimumab |
CP-675; CP-675206 |
Phase Ⅲ |
Pfizer, Amgen, MedImmune |
Urogenital cancer, Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Mesothelioma, Solid tumours, Liver cancer, Head and neck cancer |
Details
|
MEDI-5752 |
MEDI-5752 |
Phase Ⅰ |
MedImmune |
Solid tumours |
Details
|
Zalifrelimab |
AGEN-1884; RebmAb-600 |
Phase Ⅱ |
Ludwig Institute for Cancer Research, 4-Antibody, Agenus, Recepta biopharma |
Non small cell lung cancer (NSCLC), Cervical carcinoma |
Details
|